Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages 1821-1828

  Caudle, Abigail S ^a   Gonzalez Angulo, Ana M ^a   Hunt, Kelly K ^a   Liu, Ping ^a   Pusztai, Lajos ^a   Symmans, W Fraser ^a   Kuerer, Henry M ^a   Mittendorf, Elizabeth A ^a   Hortobagyi, Gabriel N ^a   Meric Bernstam, Funda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ESTROGEN RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; PROGESTERONE RECEPTOR; TAXANE; TAXOID;

ADJUVANT CHEMOTHERAPY; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; DISEASE COURSE; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951649921     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.3286     Document Type: Article

References (29)

1. Fisher B, Bryant J, Wolmark N, et al: Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998 (Pubitemid 28363030)
2. Bear H, Anderson S, Smith R, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006 (Pubitemid 46622110)
3. van der Hage J, van de Velde C, Julien J, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001 (Pubitemid 33081640)
4. Guarneri V, Broglio K, Kau S, et al: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006 (Pubitemid 46638799)
5. Jeruss J, Mittendorf E, Tucker S, et al: Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neo-adjuvant therapy. J Clin Oncol 26:246-252, 2008
6. Kuerer H, Newman L, Smith T, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999 (Pubitemid 29075229)
7. Hess K, Anderson K, Symmans W, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast can. J Clin Oncol 24:4236-4244, 2006 (Pubitemid 46630780)
8. Rouzier R, Perou C, Symmans W, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685, 2005 (Pubitemid 41170290)
9. Nolen B, Marks J, Ta'san S, et al: Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10:R45, 2008
10. National Cancer Institute, Surveillance Research Program, Cancer Statistics Branch: Surveillance Epidemiology and End Results Program (SEER) Stat Database: Mortality-all COD, Public-use with state, total U.S. for expanded races/Hispanics (1990-2001). http://www.seer.cancer.gov/
11. Ayanian J, Kohler B, Abe T, et al: The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 329:326-331, 1993 (Pubitemid 23210686)
12. Bauer K, Brown M, Cress R, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109:1721-1728, 2007 (Pubitemid 46668532)
13. Bradley C, Given C, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490-496, 2002 (Pubitemid 34411287)
14. Carey L, Perou C, Livasy C, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006 (Pubitemid 43854964)
15. Dawood S, Broglio K, Kau S, et al: Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220-226, 2009
16. Symmans W, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4425, 2007
17. Kuerer H, Sahin A, Hunt K, et al: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230:72-78, 1999 (Pubitemid 30190367)
18. Pierga J, Mouret E, Dieras V, et al: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83:1480-1487, 2000
19. Faneyte I, Schrama J, Peterse J, et al: Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 88:406-412, 2003 (Pubitemid 36308152)
20. Dowsett M, Dunbier A: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14:8019-8026, 2008
21. van de Vijver M, He Y, van't Veer L, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
22. Perou C, Sorlie T, Eisen M, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000
23. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004 (Pubitemid 40051905)
24. Acharya C, Hsu D, Anders C, et al: Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299:1574-1587, 2008 (Pubitemid 351482796)
25. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005 (Pubitemid 46202341)
26. Thuerigen O, Schneeweiss A, Toedt G, et al: Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24:1839-1845, 2006
27. Chang J, Wooten E, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003 (Pubitemid 36957839)
28. Cronin M, Sangli C, Liu M, et al: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53:1084-1091, 2007 (Pubitemid 46867525)
29. Buzdar A, Ibrahim N, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3684, 2005